Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis: how diet may be associated with better outcome and management

Virginia Thornley, M.D., Neurologist, Epileptologist

February 27, 2018

Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder resulting in muscle weakness, atrophy and eventual respiratory failure. It involves mitochondrial dysfunction, oxidative stress, apoptosis, neural inflammation, metallic accumulation, decreased trophic factors, glutamate activation, and superoxide dismutase-1. There is a growing interest in the role of diet in the natural progression and treatment. Risk of ALS may increase with increased intake of macronutrients such as carbohydrates, glutamate, and fat and a reduced intake of micronutrients such as carotenoids, fruits and vegetables, polyunsaturated fatty acids and Vitamin E. Oxidative stress may also increase the risk of ALS.

29727_414398748840_6053518_n

 

Good food versus bad food in ALS

In one study of 306 patients in over 16 ALS centers, milk and lunchmeat seemed to correlate with a negative ALS function using the ALSFRS score (ALS functional rating score) or the percentage FVC (forced vital capacity) for the outcome. Milk and lunchmeat are associated with higher fat and potentially promote oxidative stress. It studied foods that were considered good (calcium, iron, potassium, iron, thiamine, riboflavin, niacin, zinc, selenium, vitamins C, D, E, K, and B6, magnesium, and glutathione) versus bad(phosphorus, caffeine, food-producing high glycolic index). The components of the good food groups had eggs, poultry, fish, beneficial oils and vegetables and are often associated with anti-oxidants and a healthy diet. The study only provides an association not a causation of good food towards a better outcome. Food high in fiber, carotenoids, and antioxidants provided a better outcome(1).

Another study noted that patients with the lowest score of ALSFRS appear in those with the lowest intake of vegetables, grains, oils, and seasonings (3).

Novel treatments using diet

In one study using a high caloric diet and an MAO-inhibitor/iron-chelating compound  M30 in the superoxide dismutase-1 mouse model, results showed neuroprotection involving motor function and increased survival in the SOD-1 G93A transgenic mouse model. The M3 and CED (high caloric diet) resulted in increased mitochondrial biogenesis and metabolic regulators. A combination of novel approaches may help treat this condition (2).

10453099_10152610186308841_4605634303197056211_o

1. Nieves, et al, “Association between dietary intake and function in Amyotrophic lateral sclerosis, ” 2016, Dec., 73 (12)1425-1432.

2. Golko-Perez, et al, “Additive Neuroprotective effects of the multifunctional iron chelator M30 with enriched diet in a mouse model of amyotrophic lateral sclerosis,” Neurotoxicity Research, 2016, Feb., 29(2):208-217.

3. Park, et al, “Association between nutritional status and disease severity using amyotrophic lateral sclerosis (ALS) functioning rating scale in ALS patients”Nutrition, 2015, Nov.-Dec., 31(11-12):1362-7.

Standard
Epilepsy

Ketogenic diet and its variants modifed Atkins diet, low glycemic index treatment: effectiveness, side effect profile in patients with epilepsy and incidental weight loss

Virginia Thornley, M.D., Neurologist, Epileptologist, February 26, 2018

Doctors first took notice of the ketogenic diet working in patients with epilepsy in the 1920’s. But the exact mechanism remains unclear. One study elucidated that the ketone bodies are one of the reasons why the ketogenic diet works in patients with epilepsy. Ketosis occurs during a natural fasting state. In the ketogenic diet using high fat, the by-products of beta-oxidation of fatty acids which are beta-hydroxyacetate and acetoacetate in the blood do not correlate with patients who are doing better. Medium chain triglyceride fatty acids, which are a part of a variation of the ketogenic diet, are shown to suppress the AMPA receptors which subserve the excitatory neurotransmitter glutamate and may change energy use of the cell through mitochondrial processes (1).

10453099_10152610186308841_4605634303197056211_o

Ketogenic diet and adverse effects

Some patients have difficulty adhering to the diet which makes it difficult to use. Common side effects because of the high-fat content are diarrhea, constipation, nausea, transient increase in lipemic values. Variations of the ketogenic diet are sometimes used to offset these side effects and reduce the non-compliance.

Some ketogenic variants

Ketogenic diet variants include modified Atkins diet, low glycemic index treatment, and medium chain diet. The ketogenic diet consists of 4:1 ratio of fat to carbohydrates shifting metabolism to the use of ketone bodies as a source of energy. A lower ratio is sometimes employed called the modified ketogenic diet with a 3:1 or 2:1 ratio of fat to carbohydrates. In the modified ketogenic diet, the palatability is improved and avoids the gastrointestinal symptoms associated with the ketogenic diet such as nausea. With the modified Atkins diet, carbohydrates are restricted to 10-20 grams a day, or a 1-2:1 ratio of protein to fat plus carbohydrates. In the low glycemic index treatment, carbohydrates are limited to 40-60 grams while 50-60% of the diet is fat and 20-30% is from protein. The medium-chain triglyceride diet employs oils as a supplement such as coconut oil. The palatability of these diets improve patient compliance and lessen the side effects of the ketogenic diet. Some patients also used the diets to incidentally lose weight in addition to treating seizures (2).

10467147_10152610189183841_7745525672430652445_o

Effectiveness of the ketogenic diet and ketogenic diet variants

One study summarizing studies on patients using the classic ketogenic diet found that 50% of patients out of 206 had a >50% reduction of seizures using the classic ketogenic diet. Older patients seemed to benefit less. In the modified Atkins diet, seizures were reduced in younger patients with more frequent seizures. Patients tended to drop out because of the side effects, lack of perceived effectiveness and because of the restrictions in the diet. Patients greater than 12 years old were less adherent to the diet (3).

It is possible that the protective effects of the ketogenic diet are related to the medium chain triglyceride fatty acids and not the ketone bodies.

https://neurologybuzz.com/

About

Introduction/Disclaimer

References

1. Augustin, et al, “Mechanism of action for medium-chain triglyceride ketogenic diet and metabolic disorders,” Lancet Neurology, 2018, Jan., 84-93.

2. McDonald, et al, “Ketogenic diets for adults with highly refractory epilepsy,” Epilepsy Currents, 2017, Nov.-Dec., 17(6):346-350.

3. Payne, et al, “The ketogenic and related diets in adolescents and adults-a review,” Epilepsia, 2011, Oct., 52(11):1941-1948.

Standard
multiple sclerosis

Multiple sclerosis: stem cell therapy and its role in remyelination

Virginia Thornley, M.D., Neurologist

February 25, 2018

Stem cell research is a fast-growing arm of science. Multiple sclerosis is an autoimmune disease where the central nervous system is attacked as foreign. Clinical symptoms depend on the area involved, primarily in the white matter. Scientific research is being more and more directed towards agents and treatment modalities that differ from today’s immunomodulating agents given the potentially devastating side effects of the more efficacious medications. The heavy hitters tend to be more serious adverse effects.

How stem cell administration works

Umbilical cord mesenchymal stem cells may play a significant role in tissue repair and immunomodulatory processes that are important in multiple sclerosis. Stem cells divide into different types of cells which give rise to different tissues. They hold a wealth of potential in repairing damaged tissue as that found in multiple sclerosis. In one study, the mesenchymal stem cells from the umbilical cord were found with low immunogenicity. They can inhibit the multiplication of killer cells, T lymphocytes, and B lymphocytes and can inhibit the maturation of dendritic cells. Mesenchymal stem cells migrate to the site of injury and proliferate to repair damaged tissue.

Different stem cells that can be used in multiple sclerosis

Other types of stem cells are derived from hematopoeitic, embryonic, neural, spermatogonic, adipose, endometrial, Wharton jelly surrounding the umbilical cord and pluripotent-induced stem cells.

13925802_10154408561258841_5096074368744450311_o

Stem cell administration in 2 patients and reduction of abnormal MRI abnormalities

In one study, 2 patients were treated with stem cells. Clinical symptoms were reduced in the 1st patient, they were followed 8 years and found without adverse effects. The 2nd patient progressed and the timing of stem cell administration was shortened resulting in the reduction of symptoms. The number of abnormal foci seen in the MRI of the brain was less suggesting remyelination of damaged tissue within the brain. During illness, the body increases the immunogenicity with amplification of inhibitory co-stimulatory signals. With stem cell administration, this process reduces these destructive immune processes. Umbilical cord mesenchymal cells were found to inhibit IL-17c, HLA-DRB1, and IL-2 thereby protecting against an autoimmune response. The mechanism of action by which the stem cells work favors a remyelination repairing the damaged area(1).

Stem cell research in a study of 20 patients and reduction in disability

In another larger study of 20 patients, mesenchymal stem cell neural progenitor was applied. Results showed 70% had improved muscle strength and 50% improved in bladder symptoms. Improved EDSS (Expanded Disability Status Scale) was noted in 40% of patients, there were some minor adverse effects (2).

13680208_10154408585938841_6912978101643468976_o

Larger clinical randomized case control trials are needed.

References
  1. Meng, et al, “Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis,” American Journal of Translational Research, 2018, 10(1): 212-223.
  2. Harris, et al, “Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis,” EBioMedicine, 2018, Feb., pii.S2352-3964 (18)30051-3 (Epub ahead of print)
Standard
mold

Mold exposure: adverse effects of mycotoxins can still occur long after remote exposure

Virginia Thornley, M.D., General Neurologist, Epileptologist

February 23, 2018

Introduction

Water damaged buildings produce mold with airborne spores and hyphae floating as tiny particles in the air. The mycotoxins responsible for causing disease are called classified as aflatoxins, ochratoxin, and macrocyclic trichothecene. Even with remote exposure of up to decades, the ill effects from mold and mycotoxins can still be manifest.

10551440_10152611714523841_7526391710540820046_oWhy mold can still exert its effects even after many years of exposure

Mycotoxins are the toxins emitted by the mold that cause disease. These are detectable in the body of an affected individual in the urine, serum, breast milk, placenta, and even the umbilical cord. Some common molds that can be found are Aspergillus, Penicillium, Trichoderma, Stachybotrys chartarum. Some mold can be shed as fine airborne fragments. Nasal passages can harbor fine particulate mold which is not necessarily detected by spore counts. Nasal passages can harbor these fragments causing colonization for years.

Why treatment of mold exposure can be difficult

In one study, biofilm within the nasal passages was found to be present causing resistance to treatment. Biofilms occur when the microorganisms are embedded in the extracellular matrix.  The formation of a biofilm occurs by attachment to the cell membrane, multiplication of hyphae, packing and cross-linking on the cell channel and spore formation. There is some genetic involvement which may impart resistance to antifungal treatment or an up-regulation of metabolic pathways that were established by the hyphae.

In addition, there may be an interaction of bacteria with the mold in synergy. Bacteria that are sometimes found concomitant to the discovery of hyphae in the body include Staphylococcus aureus,  which is the most common. Hemophilus influenza incurs less severe disease. Staphylococcus aureus coagulase negative is also found in nasal passages.

The biofilm acts as a wall against antifungals making patients resistant to treatment.It leads to continuous colonization and proliferation of the fungus making treatment refractory(1)

10515259_10152611708578841_5684356889525088244_o.jpgNovel modalities in reducing fungal burden

First includes avoidance of further exposure to mycotoxins. It was found that in addition to being exposed to mold, affected individuals develop hypersensitivity to other chemicals after exposure. These include pesticides, organophosphates, bisphenol, benzophenone found in sunblock, perfluorocarbons found in non-stick coatings, heavy metals and solvents among others.

Why mycotoxins cause neurological disorders

Glutathione deficiency is found in those exposed to water damaged buildings. Glutathione deficiency causes cell degeneration and severe mitochondrial destruction. This deficiency may occur in the brain resulting in mitochondrial damage which may lead to neurological symptoms. Replacement may help. Oxidative stress-mediated impairment in the mitochondria is supported in animal models with aflatoxin. Neurotoxicity is also seen from oxidative stress mechanisms.

Vitamins and substances that can help with mycotoxin toxicity including Coenzyme Q10, Vitamin A, C, B, melatonin, Ginseng and whey protein

Additional anti-oxidants may be beneficial in neurotoxic injury including coenzyme Q10, vitamin D, magnesium, zinc and B deficiencies. In one animal study, cellular changes including DNA changes could be restored using whey protein and Korean ginseng. The whey protein supplies cysteine which is the rate-limiting step in glutathione creation. Licorice extract was found protective against destructive changes in an animal model where oflatoxin was introduced. Nitrosative tissue destruction caused by aflatoxin can be reduced with melatonin supplements in another animal study. Vitamins A, C, B was studied in the human model. When human lymphocytes were exposed to aflatoxin there was reduced GSH, and superoxide dismutase and glutathione peroxidase. Simultaneous use of Vitamins A, C, and B restored these levels to normal.

https://neurologybuzz.com/

Introduction/Disclaimer

About

  1. Brewer, et al, “Chronic illlness associated with mold and mycotoxins: is nasosinus biofilm the culprit?”  Toxins, 2014, Jan. 6(1)66-80.
  2. Thrasher, et al, “Water damaged home and health of occupants: a case study,” Journal of Environmental Health, 2012, 2012:312836.
Standard
migraine

Magnesium: a natural alternative therapeutic agent for migraines

By Virginia Thornley, M.D., Neurologist

February 21, 2018

Many migraine sufferers are turning more towards all natural organic ways of managing migraines disillusioned by the side effects of conventional medications. Much attention is directed towards safe, healthy non-prescription agents in dealing with medical conditions. There is growing attention directed towards a more natural way of dealing with migraines with the incompletely effective measures that are available through conventional medicine. Several nutraceutical options are found to have growing evidence of effectiveness including magnesium, feverfew, coenzyme Q and riboflavin(1). Level B evidence exists for riboflavin, magnesium and feverfew(2). They have been found to be useful in treating the pediatric population because the risk of side effects is less(4). Many physicians practicing evidence-based medicine are still very reluctant to recommend nutraceuticals despite evidence in the literature of its effectiveness. This seeks to explore the mechanism of action and studies supporting the use of magnesium in migraine management.

13925660_10154408543883841_3219448478173697371_o

Proof is in the pudding

Doctors are reluctant to advise using supplements but there is a growing body of evidence supporting its use. In one report reviewing a wide range of studies evaluating the use of magnesium in migraine Level I evidence supports the use of magnesium in managing migraine(5). Magnesium is an important cofactor in many metabolic processes in the body. Optimizing its use appears well-documented in several medical conditions including migraine. In one study, there was a 50% reduction in the number of days with migraine using magnesium which increased in number of days the longer the supplement was used (6). With high dose IV magnesium in another study, in 93% of patients the migraine attack ended, in 1% the symptoms reduced in severity, in 100% the accompanying symptoms disappeared(7). High dose IV is a conventional treatment widely used in the hospital setting to abort debilitating migraines and often part of the “migraine cocktail” widely used in the ER setting.

13909097_10154408554898841_3094248803020579476_o

How does magnesium in a migraine work?

Magnesium is a mineral found naturally in the diet and is used in IV form to break the excruciating condition status migrainosus in the hospital setting. It is frequently used as a safe, healthy organic measure in migraine prevention. It has been found that people with migraines are magnesium deficient compared to healthy controls. Magnesium deficiency may be important in platelet hyperaggregation(3), cortical spreading depression, affect serotonin receptor function and affect many neurotransmitters and their release and functions. Migraineurs may suffer from magnesium deficiency due to genetic abnormalities, abnormal renal secretion and reduced consumption in the diet among other mechanisms. Magnesium may be deficient in more than 50% of patients warranting a trial in all migraine sufferers. It cannot be measured in the blood because most of the mineral is found in the bone at about 67% and intracellularly at 31% leaving less than 2% that can be measured extracellularly.

Consult with your neurologist.

https://neurologybuzz.com/

Introduction/Disclaimer

About

 

  1. D’Onofrio, et al, “Usefulness of nutraceuticals in migraine prophylaxis,” Neurological Science, 2017, May, 38 (Suppl1):117-120.
  2. Tepper, et al, “Nutraceutical and other modalities of treatment for migraine,”Continuum: Lifelong Learning, 2015, August, 21 (4, Headache);1018-31.
  3. Mauskop, et al, “Why all migraine patients should be treated with magnesium,”Journal Neural. Transm., 2012, May, 119(5):575-579.
  4. Sangermani, et al, “The use of nutraceuticals in children’s and adolescent’s migraines,”Neurological Science, 2017, May, 38 (Suppl 1):121-124.
  5. Schwalfenberg, et al, “The importance of magnesium in clinical healthcare,” Scientifica (Cairo), 2017:4179326.
  6. Guilbot, et al, “A combination of coenzymeQ10, feverfew and magnesium for migraine prophylaxis: a prospective observational study,” BMC Complement. Altern. Medicine, 2017, Aug., 30 (7):433.
  7. Demirkaya, et al, “Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks,”Headache, 2001, Feb., 41(2):171-7.
Standard
Epilepsy, Uncategorized

Dravet syndrome: clinical course, SCN1A genetic abnormality involved and non-pharmacologic options including ketogenic diet and cannabidiol

By: Virginia Thornley, M.D., Epileptologist, General Neurologist

February 20, 2018

Dravet first described the syndrome that now bears his name in 1978. It is now a model for some of the channelopathies seen manifesting as epilepsy.

Clinical course and electroencephalographic manifestations

Dravet syndrome is also known as the severe myoclonic epilepsy in infancy (SMEI). Patients usually have no delay in development prior to the first seizure. It usually starts between 5-8 months of life another report mentions after 2nd year of life and may follow a febrile seizure. It consists of generalized tonic-clonic seizures and myoclonus. The term severe myocolic epilepsy of infancy (SMEI) is a misnomer as some patients with this gene related disorder may not manifest with myoclonus so Dravet syndrome is preferred. Clinical evolution includes an initial presentation of generalized tonic-clonic seizures evolving into multiple seizure types predominantly myoclonus. Complex partial seizures, focal seizures, and atypical absence seizures may be identified. Myoclonus is seen about 2 years of age and eventually disappears. The generalized type of seizures persists into adulthood. The EEG background becomes progressively slower, with poor organization. There is the presence of excessive frontal theta rhythms and discharges consist of spike, spike and wave and polyspike and wave complexes. There is sensitivity to fevers. It is usually associated with cognitive impairment. Lifespan is unclear as case series are not reported on those after 20 years of age (1).

SCN1A gene

Dravet syndrome is found to be one of the SCN1A-related disorders causing seizures. Genetic testing reveals a heterozygous variant of SCN1A. SCN1A encodes Nav1.1 or the alpha subunit of the voltage-gated sodium channel. Seizures related to this channel are channelopathies. Due to the molecular abnormality at the level of the channel, there is hyperexcitability due to the imbalance of excitation versus inhibition because of neuronal dysfunction at the level of the sodium channel. The SCN1A is encoded on chromosome 2q24 which also includes SCN2A and SCN3A. In epilepsy-associated variants which are all found in the Nav1.1 alpha subunit, they are more frequently found in the C-terminus, and some in the N-terminus. In Dravet syndrome, nearly 50% are truncating variants, while others are splice, missense or deletion types of abnormalities.  The pathophysiology is an area under intense investigation but likely due to loss of the excitability of inhibitory function of the GABAergic pathway causing seizures(4).

Non-pharmacologic ways to deal with conditions of Dravet syndrome

Anti-convulsants to avoid

Prescription agents are not discussed as new agents become available year to year. However, there are medications that should be avoided including carbamazepine, lamotrigine, vigabatrin, and phenytoin. Rufinamide is a similar agent to carbamazepine and could theoretically worsen this condition. Sodium channel blockers like these worsen these types of seizure. In Dravet syndrome,  there is an abnormality of voltage-gated sodium channel Nav1.1, where one would think there would be fewer seizures following the thinking that sodium channel blockers are used anticonvulsants. However, with the sodium channel abnormality in SCN1A seizure disorders, there is more inhibition of the GABAergic pathway which keeps seizures in check thus, there are more excitatory neurotransmitters available causing seizures to occur(4).

Ketogenic diet and mechanisms of action

The ketogenic diet has been found to improve the condition. With ketogenesis, instead of glucose being used as a substrate for seizures, there are increased ketones available from a high fatty acid diet in the body meaning less available glucose that helps keep up the metabolism required with energy expenditure used in seizures. The body uses ketones as the fuel source. Ketogenesis occurs with natural fasting when the body breaks down fat through lipolysis. Then, the fatty acids produced undergo beta-oxidation into ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone) which are used to produce energy ATP (adenosine triphosphate) used by the cells(3). The ketogenic diet mimics this natural process by using a high fat low carbohydrate diet so that instead of glucose the body uses fatty acids which turn into ketones used as a fuel source which is not conducive to seizures.  With ketogenic diet as a therapeutic option, it is key to see a dietician as the diet is strictly high fat. It is based on a tightly regimented all or none principle otherwise it will not work. Most patients eventually find the diet highly unpalatable and may give up. However, if followed faithfully, it may be a viable non-pharmacologic additional option in medically refractory patients with seizures. One study found a 62% reduction rate in Dravet syndrome using the ketogenic diet(2). In the study, the EEG significantly improved and a favorable outcome was seen in those with a shorter duration of the condition and those with generalized tonic-clonic seizures. However, like most studies of rare diseases the number studied was small.

10429450_10152610208453841_6861894890174598213_n

Other mechanisms proposed include changing the pH of the brain making it less favorable for the production of seizures, direct inhibition of ion channels by ketone bodies, and changes in amino acid metabolism to favoring GABAergic synthesis which is inhibitory to seizures.

Cannabidiol in Dravet syndrome

One study examining the effects of cannabidiol (CBD) on Dravet syndrome postulate mechanisms including increasing excitation of the inhibitory effect of the hippocampus where seizures are propagated.  At low doses, it helps with autism and impaired cognition.  It may exert its effect by working against GPR55. The effects of CBD on neurotransmitters were similar to the GPR55 antagonist suggesting CBD works at the level of this lipid-activating G-protein coupled receptor(5).

Consult with your neurologist.

About

Introduction/Disclaimer

https://neurologybuzz.com/

 

References

1. Akiyama, et al, “Dravet Syndrome: A Genetic Epileptic Disorder,”Acta Med. Okayama, 2012, 66(5):369-376.

2. Dressler, et al, “Long-term outcome and tolerability of ketogenic diet in childhood epilepsy— the Austrian experience,”Seizure, 2010, Sept., 19(17):404-408.

3. Maranano, et al, “The ketogenic diet: uses in seizures and other neurologic illness,” Current Treatment Options in Neurology, 2008, Nov., 10(6)410-419.

4. Miller, et al, “SCN1A-Related Seizure Disorder,” Gene Reviews, 2007, Nov., Updated 2014, May.

5. Kaplan, et al, “Cannabidiol attenuates seizures and social deficits in a mouse model in Dravet syndrome,” Proceedings of the National Academy of Science, 2017, Oct.

 

Standard
multiple sclerosis

A summary and comparison of the different immunomodulating agents used in multiple sclerosis

Virginia Thornley, M.D., Neurologist

February 17, 2018

Introduction

Research on multiple sclerosis occurs at a dizzying rate. Because there are many newer agents on the market, the treatment options may be confusing for both the patient and even for neurologists wading through a large morass of novel therapeutic options. This seeks to compare and summarize the most current immunomodulating agents in a quick and concise way based on the package inserts, original drug websites and clinical trials performed. It reviews the most common and most striking potential serious side effects, the annual relapse rate reductions and effects on brain MRI lesions (abnormalities in the brain). Some agents were tested against placebo (placebo is an agent with no medicine in it used in comparison studies) others were against older immunomodulatory agents which were previously the gold standard. Currently, there are no head to head clinical trials comparing each immunmodulating agent against each other.  They are listed according to efficacy based on a reduction in annual relapse rate, although some authorities might prefer to compare the effect on MRI lesion burdens. Of note, the most efficacious agents also have some of the most potentially devastating side effects, including cancer and progressive multifocal leukoencephalopathy (PML) which is an irreversible destructive process affecting white matter in the brain occurring in the immunosuppressed state. Consult your neurologist.

 

Older immunomodulating agents

Avonex, Betaseron, Copaxone, Rebif

Mechanism of action: immunomodulation

Efficacy is about 23-25% all very similar

Side effects: flu-like symptoms, transaminitis

Pros: least amount of significant side effect

Cons: least efficacious

 

Newer agents

Aubagio (teriflunomide)

Mechanism of action: reduces B and T cell lymphocyte proliferation, inhibits DHODH required for rapidly dividing cells, exact mechanism is unknown

Efficacy: 30% relative risk reduction in TEMSO trial, 36% ARR (annualized relapse rate)reduction in TOWER trial

57% relapse-free after 108 weeks

Side effects: hepatotoxicity (can cause liver problems), teratogenesis (can affect fetus), bone marrow suppression, hypersensitivity

Pros: efficacious compared to older agents, to date still no reports of PML post-market

Cons: very little

 

Plegridy (peginterferon beta-1a)

Mechanism of action: reduces antigen presentation and proliferation, alters cytokine and matrix metalloproteinase

It is delivered by pegylation, where the medicine is bound to a glycol such that there is reduced renal clearance. Thus, delivery is long spanning 2 weeks.

Efficacy: 36% reduction in ARR

38% reduction in disability progression

Side effects: flu-like symptoms, seizures, suicidal ideations, anaphylaxis, congestive heart failure, autoimmune disorder, abnormal liver enzymes

Pros: efficacious

Cons: very little

 

Ocrevus (ocrelizumab)

Mechanism of action: Ab that target cells with B lymphocytes, Ag CD20 this results in less Ab-dependent cytolysis and complement-mediated lysis

Efficacy:  47% ARR reduction compared with Rebif in RRMS (relapsing-remitting multiple sclerosis)

24% less likely to have a disability in PPMS (primary progressive multiple sclerosis)

Side effects: infusion reactions, hepatitis B reactivation, you cannot receive live vaccine, possible breast cancer

Pros: efficacious

Cons: concern for progressive multifocal leukoencephalopathy found in 1 patient post-marketing, possible breast cancer

 

Tecfidera (dimethyl fumarate)

Mechanism of action: nicotinic receptor agonist, mechanism is unknown

Efficacy:  49% ARR reduction in the DEFINE and CONFIRM clinical trials

38% delay in disability progression compared with placebo

85% reduction in new MRI lesions

Side effects: anaphylaxis, lymphopenia, abnormal liver enzymes, liver injury

Pros: oral, efficacious

Cons: PML found in 1 patient during the clinical trial, few more cases found post-marketing

 

Lemtrada (alemtuzamab)

Mechanism of action: binds to CD52 and depletes T and B cells

Efficacy: 49% less relapses compared with Rebif

65% relapse-free compared to 47% in patients with Rebif

Side effects: joint pain, infections, autoimmune diseases, lymphomas, breast cancer, skin cancer, thyroid cancer and lymphoproliferative cancer, infusion reactions

Pros: efficacious

Cons: Can cause serious autoimmune diseases, lymphomas, breast cancer, skin cancer, thyroid cancer and lymphoproliferative cancer, infusion reactions
Gilenya (fingolimod)

Mechanism of action: immunomodulation, works on the sphingosine 1-receptor modulator

Efficacy: 52% reduction in ARR compared with Avonex

82% reduced disability progression

38% reduction in T2 lesions

60% reduced T1 gad + lesions

Side effects: most common are headache, transaminitis, bradycardia (low heart rate), PML, heart block, PRES or posterior reversible encephalopathy syndrome (reversible damage to the posterior portion of the brain), basal cell carcinoma, teratogenicity

Pros: very efficacious compared to older agents

Cons: some of the worst side effects include PML, PRES, macular edema (swelling of the optic disc)

 

Tysabri (novantrone)

Mechanism of action: blocks alpha-4 integrin, an adhesion molecule on vascular endothelium, reduces activation of autoimmune cells

Efficacy: 67% reduction in ARR compared with placebo

85% reduction in new MRI lesions

Side effects: PML, herpes simplex virus, infections, abnormal liver enzymes, bradycardia, heart block

Pros: efficacious

Cons: risk of PML, bradycardia, heart block

 

In summary, the least efficacious medications are the most benign in terms of side effect profile, while the strongest immunomodulators have the more devastating potential side effects. While clinical trials reflect beneficial conclusions, attention must still be directed towards potential side effects occurring over a prolonged time which may not be reflected in clinical trials which usually involve a timeframe of a few years and do not span over decades. The real test is in the post-marketing groups.  Speak to your neurologist. See package insert for more complete information of side effects.

Introduction/Disclaimer

About

https://neurologybuzz.com/

 

 

 

Standard
Epilepsy, pain

Cannabidiol: Is there any scientific evidence? Review of some of the novel mechanisms of action in analgesic, anti-epileptic, anti-inflammatory, anti-tumorigenic and anxiolytic effects 

Virginia Thornley, M.D., General Neurologist and Epileptologist

@VThornleyMD

February 16, 2018

Introduction

Cannabidiol (CBD) is the little known medical component without the euphoria used for medical indications such as analgesic, anti-inflammatory, anti-epileptic and anxiolytic effects. In the pathway for endocannabinoids, cannabinoid exerts its therapeutic effects by binding to the CBD1 receptor found in the brains and the nerves exerting their analgesic effects. CBD does not have the same euphoriant effect as THC its counterpart which is better known to the public with much stigma. CBD will need to be 100 times more potent to have the same euphoria as THC making it relatively safe to give without the intoxicating effects. THC or delta-tetrahydrocannabidiol is the main psychoactive component in the marijuana plant, the one finds in the street drugs which has caused such a stigma shadowing the beneficial effects of the plant. Cannabidiol is also thought to work on the 5HT1 receptor giving its anxiolytic properties. This review seeks to understand some of the laboratory research that study the underlying mechanisms for its beneficial actions.

Cannabidiol works on CBD1 receptor and is thought to have an analgesic and anti-inflammatory role in diseases. In many states, it still outlawed to have in possession but growing clinical evidence shows that it can be used in pain syndromes. In the state of Florida there are 10 conditions recognized that can be treated with CBD. It is most commonly used in pain from stage IV metastatic cancer. Cannabidiol has been found to have anti-inflammatory, anti-tumorigenic, analgesic, anti-epileptic and anxiolytic properties.

Analgesic effects

CB1 receptors are found to be expressed in anterior horn cells. The CB2 receptors possibly reduce pain by acting on the neutrophil accumulation and mast cell degranulation which can reduce pain both of these processes increase inflammatory algesia(1).Analgesia has been demonstrated with cannabinoids in visceral inflammation and pain due to peripheral neuropathies, important areas of therapeutic considerations.

Anti-seizure effects

Some of the vast scientific research for cannabinoid is found in the animal models for epilepsy. Cannabinoids exert effects on CB1 and CB2 receptors in the hippocampus where it has a weak affinity(5). CBD1 receptors affect transmission in the synapses through the voltage-gated calcium and potassium channels. There are studies on the effects of CBD in refractory types of epilepsy such as Dravet’s syndrome one of the SCN1a genetic disorders affecting the sodium channel manifesting as severe myoclonic epilepsy. Mechanisms of CBD include increasing excitation of the inhibitory effect of the hippocampus where seizures are propagated.  At low doses, it helps with autism and impaired cognition.  It may exert its effect by working against GPR55(7), TRPV1 in addition to voltage-gated voltage-gated potassium and sodium channels. Another study supports the role that cannabinoids may play in shifting the inhibition of glutamatergic effects and GABAergic effects in the hippocampus mediated by CB1 receptors. In the rat model, it was suggested that seizures can upset the balance of these glutamate and GABA systems (4). 15 minutes after an induced seizure, there is increased 2-arachidonylycerol which is a CB1 agonist suggesting cannabinoids act as a negative feedback loop for seizures(4). In addition, it was found there are more CB1 receptors in the hippocampi with induced seizures compared to control suggesting plasticity of the brain with a compensatory increase in CB1 receptors in response to increased seizures(4). CB2 receptors are related to the immune system and are limited in the CNS. Cannabinoids affect calcium homeostasis and may provide its neuroprotective effects. Growing evidence shows case series, case reports and anecdotal reports on patients having fewer seizures on cannabidiol. Large case-controlled clinical randomized trials are needed.

Anti-tumor effects

There appears to be increased cancel cell death, reduced viability and reduced numbers of metastatic cells. In one study, it is found to reduce epidermal growth factor-induced multiplication and chemotaxis of cells in breast cancer. In mouse models, it inhibits macrophage recruitment in tumor-related cells.n It can potentially inhibit metastasis and proliferation and may provide a novel therapeutic option in breast cancer(2).

Anxiolytic effects

It works on the 5HT1 receptor by altering effects on this receptor the exact mechanism is unknown accounting for anxiolytic properties(6).

1383715_10151936144383841_1962894181_n

Anti-psychotic effects

CBD may alter the effects of THC and reduce its psychoactive properties (6).

 

Alternative treatment in opioid use

CBD might also work in place of opioids with the growing epidemic of chronic pain and overuse of opioids, CBD may be an alternative analgesic for chronic pain without the effect of tolerance or sedating properties. CBD was found to reduce the reward effects of morphine and does not have the same properties of tolerance. CBD does not have the same euphoria and THC and works on pain(6).

In summary, it is an exciting time for research in the use of cannabinoids. There are innumerable basic science research studies demonstrating the therapeutic effects at the cellular level. Large randomized clinical trials are still needed to gain information in using cannabinoids in humans.

Introduction/Disclaimer

About

https://neurologybuzz.com/

References

1. Rice, AS, et al, “Endocannabinoids and pain: peripheral and spinal analgesia in inflammation and neuropathy, ” Prostaglandins, Leukotrienes and Essential Fatty Acids, 2002, Feb., 66(2-3)246-256.

2. Elbaz, E. et al, ” Modulation of tumor microenvironment and inhibition of EGF/EGFR pathway: novel mechanisms of Cannabidiol on breast cancer,”Molecular Oncology, 2015, Apr., 9(4):906-919.

3. Welty, W.E., et al, “Cannabinoids: the promises and pitfalls,” Epilepsy Currents, 2014, Sep.-Oct., 14(5):250-252.

4. Wallace, MJ, et al, ” The endogenous Cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy, ” The Journal of Pharmacology and Experimental Therapeutics, 2003, Oct., 307(1):129-137.

5. Gaston, T. et. al, “Pharmacology of cannabinoids in the treatment of epilepsy, ” Epilepsy Behavior, 2017, May, 70:313-318.

6. Volkow, Nora, “The biology and potential therapeutic effects of cannabidiol,” National Institute on Drug Abuse Senate Caucus on International Narcotics Control, 2015, June.

7. Kaplan, et.al, “Cannabidiol attenuates seizures and social deficits in a mouse model in Dravet syndrome, “Proceedings of the National Academy of Science, 2017, Oct.

Standard
stroke

Stroke: Dealing with Life after Stroke

By Virginia Thornley, M.D., Neurologist
February 15, 2018

Introduction
A stroke occurs when a blood vessel in the brain or neck becomes blocked by a clot which migrated or a plaque that broke interrupting flow to areas in the brain. The neurological symptoms depend on the area involved with the blockage of the artery. A patient who suffered a stroke will often be advised a work-up to determine the etiology of whether the clot came from the heart, aorta or from a large vessel in the neck or brain. Treatment depends on the etiology of the source.

How to manage life after a stroke
Stay healthy
Many risk factors are involved in stroke including diabetes mellitus, hypertension, obesity and high cholesterol. These contribute towards the formation of atherosclerotic plaques in the arteries which can break and block an artery. Ensuring risk factors for stroke are under good control is key. Keep active.

If motor function is involved
If the motor function is involved it is important to have frequent physical therapy to avoid contractions. Contractions occur when a part of your body is not moving, the 19059671_10155427294453841_913446057479861555_nmuscles stay in a contracted state and eventually becomes immobile. Passively moving the limb keeps it supple. Patients can recover function the most in the first 6 months of intense rehabilitation, therefore, the importance of a good physical therapist working cannot be emphasized enough. If large parts of the brain are involved, with intensive physical therapy, sometimes there are other parts of the brain that undergo a process called cortical reorganization where it can overtake the function of the damaged part of the brain. The more intense the therapy the higher the chances of maximal recovery. It is not an exact science but recovery depends on the severity of the stroke.

For many patients, the weakness is persistent even after physical therapy is discontinued. Exercises at home without the physical therapist is still very helpful. Sometimes, the therapist will give a list of exercises to continue at home before services are discontinued. The more therapy is done the chances of meaningful recovery increase. Physical therapy helps with balance and vertiginous (spinning sensations) symptoms as well.

If speech is involved
A good speech pathologist is essential in regaining language. If the problem involves articulation or the motor component of speech, exercises involving the lips, tongue or palate are advised depending on which muscles are affected. With facial muscle involvement, the muscles of the mouth are affected. Exercises with the letter “m” are helpful such as repeating “ma-ma-ma”. Lingual muscles can be strengthened repeating words or sounds with the letter “l” such as “la-la-la”. Palatal muscles are the deeper muscles of the throat. These can be strengthened with guttural sounds such as sounds with the letter “g”, with the hard sound in it such as saying “ga-ga-ga” repetitively.  A speech therapist gives specific exercises to strengthen the weak muscles of articulation.

If verbal output is affected, or the ability to produce sound and words, encouragement to keep speaking even if no sounds occur is important. The more one attempts to speak the more the nerves are engaged and actively firing. With each day, neural connections are strengthened in the brain until eventual language output is achieved. Speech output has the best chances of complete recovery.

If the problem is related to reception or comprehension of language, a speech therapist is helpful in rehabilitation. Other ways to rehabilitate include the following:

1. Have conversations with the patient in order to engage with him or her.
2. Label objects at home will so he or she absorbs, reads, recognizes the word and understand.
3. Speak to patients slowly and enunciate well.
4. Teach the functions of items, for example, ask the patient what does an iron do? Proceed to demonstrate and explain it takes out wrinkles.

5. Have a corkboard with pictures with names and functions written under each picture. Go over them each day.  This can be changed frequently.
6. Point to objects and name them. Explain the functions while out and about or even at home.

The more a patient with language difficulties is engaged, the more the cortex will rewire to form new connections. Early and intense rehabilitation is key.

If the weakness is mild
Sometimes a stroke can affect a small yet vital part of the body with a very important function such as the dominant hand. In cases like these, occupational therapy is very useful.  Exercises that can be done at home include picking up cards, putting small objects in a box and taking them out or squeezing and squeezing a ball. Picking up small coins few times a day in several sets can help.

10458558_10152606874038841_6990278686478731439_n.jpg

The best recovery is seen within the first few months of a stroke. However, the brain is still capable of recovering long after a stroke depending on the size and location but starts to slow after longer periods of time. It varies per individual. The motor component for language meaning the ability to say words is easier to recover than the comprehensive function meaning the ability to understand words.

Every stroke is unique and special services depend on the area of the brain involved and the function that is affected. While the brain still has the ability for cortical reorganization, or the ability of some parts of the brain to take over the function of the damaged part of the brain, early and intense rehabilitation is vital.

Introduction/Disclaimer

About

https://neurologybuzz.com/

Standard
stroke

A Review on “Low Dose Aspirin and Intracranial Hemorrhage, ” by Soriano, L.C., et.al, Neurology, 2017

Reviewed by Virginia Thornley, M.D., Neurologist

This study asks if low dose aspirin in the 75-300 mg range causes an increase in the risk of intracranial hemorrhage. A national database in the UK was used which identified 199,079 new users of aspirin, each was matched to a patient with no aspirin use.  Patients were taken from the 1st year of general practice. Those who had liver cirrhosis, cancer, esophageal varices were excluded. Ten thousand controls were sampled in the cohort. Cases were divided into intracranial hemorrhage, subdural hematoma, subarachnoid hemorrhage and fatal. Case control methods were used using a confidence interval of 95% with logistic regression. 1611 patients were found with intracranial bleed after following the patients for 5.4 years.

They found that in 400,000 patients followed for 14 years, low dose aspirin showed did not correlate with an increased risk of intracranial hemorrhage or subdural hematoma. Although most used 75mg, at a dose of 80-300mg it is unclear. Using low dose aspirin for at least 1 year showed a protective effect against subarachnoid hemorrhage. This study found that hemodialysis, renal dysfunction and warfarin use increases the risk of intracranial bleeding. Previous intracranial hemorrhage was associated with an 8-fold risk of a rebleed. Other risk factors increasing risk of intracranial bleed include previous ischemic stroke, smoking history, underweight, history of falls and dementia.

Summary
In summary, this is a large study concluding that intracranial hemorrhage is not related to low dose aspirin at 75 mg and is, in fact, protective against subarachnoid hemorrhage at greater than 1 year. Further studies, however, are needed for dosages at 80-300mg to determine a correlation.

Introduction/Disclaimer

About

https://neurologybuzz.com/

  1. “Low-dose aspirin and the risk of intracranial bleed, an observational study in UK general practice,” Soriano, L.C., et.al, Neurology, 2017; 22: 2280-2287
Standard